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Case Report
AbstractIn 2013, two cases of malignant solitary fibrous tumours (MSFTs) were diagnosedin Malta. Both were inoperable at presentation. Both tumours expressedplatelet-derived growth factor receptor (PDGFR) with no mutations and thetyrosine kinase inhibitor imatinib was prescribed. Nonetheless, treatment was notas effective as documented in previous case-reports.
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1. IntroductionFirst described in 1931 by Klemperer and Rabin, solitaryfibrous tumour of the pleura (SFTP) is a mesenchymalneoplasm that usually involves the pleura.1 SFTP is morecommon from the fourth till the sixth decades of life andoccurs with equal frequency in both genders. Only about800 cases of solitary fibrous pleural tumours have beenreported in the medical literature.2 The majority of theseare benign (80%) however rare cases of malignancyhave been reported3.It can occur in other thoracic areas (pericardium, lungand mediastinum) as well as in extra-thoracic areas(salivary glands, epiglottis, meninx, thyroid, breast andkidneys).5, 6 In over half of the patients the tumour isasymptomatic, but the patient may present with cough,chest pain and dyspnoea. Complete en bloc surgicalresection is the treatment of choice.3Biologically MSFT of the pleura behave unpredictably.These also have a low sensitivity to conventionalchemotherapy.7,8 A previous case-report showedevidence of the activity of imatinib in a symptomaticpatient with a chemo- and radio-resistant advancedMSFT with platelet-derived growth factor receptor(PDGFR) expression, who survived 21-months andshowed reduction in tumour metabolism6. It wassuggested that the tyrosine kinase inhibitor imatinibshould be considered for patients with recurrent orunresectable MSFTs with PDGFR expression7. There is
no data available that the absence of PDGRF expressionof the tumour leads to resistance of the tumour.
2. Cases Presentation
2.1 Case 1A 67-year-old gentleman was referred to casualty forfurther investigation and treatment of dyspnoea and drycough worse on lying down. He was an ex-smoker,hypertensive and used to work as a groundsman but hadno previous exposure to asbestos. Three monthspreviously the patient was reviewed by his GP and achest X-ray (CXR) showed a small left-sided pleuraleffusion (Figure 1). During that occasion, the patient wasnot investigated further. However on this currentadmission a CXR at casualty showed a large left-sidedpleural effusion (Figure 2).A computed tomography (CT) of the thorax was donewhich confirmed the left-sided pleural effusion withcollapse of the lower lobe of the ipsilateral lung. A hugemass with calcifications and smaller satellite masseswere detected in the left hemithorax (Figure 3). A chestdrain was inserted and after drainage of the pleuralfluid, a large mass was revealed (Figure 4).Pleural fluid was sent for cytology on two separateoccasions both reporting absence of malignant cells.
(A part of this research was presented at European Respiratory Society Congress, which was held from September 26-29, 2015 in Amsterdam,
Netherlands.)
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Bronchoscopy was carried out and bronchial brushingand lavage did not reveal any malignant cells.
Figure 1: CXR done by GP three months prior topresentation at casualty.
Figure 2: Medical imaging done at casualty on presentation.
Figure 3: CT thorax showing a mass within the left pleural effusion.
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Figure 4: Left sided chest drain in situ. Left pleural effusionand mass in the left hemi-thorax.Histology of core biopsies from the left pleural tumourshowed a spindle-cell lesion with cells arranged aroundvascular spaces in a haemangio-pericytomatous pattern(Figure 5). The cells were positive for CD34, CD99 andbcl2-markers for a solitary fibrous pleural tumour. Thepresence of high mitotic activity, atypical mitotic figuresand foci of necrosis favour the malignant variant of thetumour (Figure 6). On immunostaining for CK, SMA andDesmin, the tumour was negative. A diagnosis ofmalignant solitary fibrous tumour was made due tostrong diffuse CD34 positivity.During thoracotomy the pleural tumour was found to bediffuse and infiltrating the chest wall and lung andpartial pleurectomy was performed.The patient was started on imatinib 400 mg daily butthere was no tumour regression and after 4 months hesuccumbed to the disease.
Figure 5:Malignant Solitary fibrous tumour (X10).
Figure 6:Mitosis and atypia in pleural tumour (X20).
2.2 Case 2A 58-year-old gentleman presented to casualty withright shoulder pain and right-sided pleuritic chest painassociated with dyspnoea at rest especially when lyingdown. Patient denied haemoptysis but claimed he haddecreased appetite and weight loss. He washypertensive, ex-smoker (stopped 20 years previously)and worked as a street cleaner. The patient was treatedfor colonic adenocarcinoma (Duke B classification) withan anterior resection in 1987 and follow upcolonoscopies were always negative to malignancy.A CXR on presentation showed a right pleural effusionand a mass in the right lung base could not be excluded(Figure 7). A CT thorax showed small right subpleuraleffusion together with consolidation in the right lowerand middle lobes (Figure 8).
Figure 7: Chest X-ray on presentation.
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Figure 8: CT scan on presentation.
Figure 9:Mitosis and atypyia in spindle shaped cells with high level of mitosis (X10).
Figure 10: CT scan three months after presentation showing disease progression.
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The patient was referred for radical resection but it wasunsuccessful due to extensive invasion of the tumourinto both the thoracic wall and lung. Biopsies from thepleural mass represented a spindle cell neoplasm withincreased cellularity, overlapping nuclei, cytologicalatypia, pleomorphism and high mitotic activity (6 per 10HPF) (Figure 9). The tumour infiltrated fatty tissue in aninvasive growth pattern. Minor foci of necrosis wereseen. On immunohistochemistry, the cells were negativefor mesothelial markers (CK, Calretinin, CK 5/6) as forthe many other spindle cell markers (Desmin, S-100,CD99, B catenin, CD 34, CD117). Positively stained cellswere present on SMA and BCL2 only. Melanomamarkers/angiomyolipoma markers were also negative.The tumour showed positivity for p53 and Ki67 labellingindex in approximately 80% of the cells. Themorphology and the immunohistochemistry results ofthe tumour (CD34 negative, bcl-2 and SMA positive)were suggestive of a malignant solitary fibrous pleuraltumour.The patient was reviewed by the clinical oncologist whostarted him on imatinib 400mg daily with no regressionof the tumour. CT thorax done three months after thefirst CT showed progression of the disease withincreased right-sided pleural effusion (Figure 10).There were left lung metastasis and a smaller left-sidedpleural effusion.The patient continued to complain of increasingright-sided chest pain despite being started on a numberof analgesics. A bone scan showed no bone metastasis.An elective right intercostal nerve block was donewithin two months of presentation. The patient passedaway four and a half months from presentation.In both patients imatinib was started without priorknowledge of the PDGFR expression status because thefacility is not available in the country. Thus, the tumourspecimens had to be sent abroad after both patientswere started on this tyrosine kinase inhibitor. Nomutations in PDGFR-α and PDGFR-β and in c-KIT hotspots were detected in these two patients and bothshowed clinical and radiological disease progression inspite of imatinib treatment.
3. Discussion and ConclusionWe herein described two cases of a 67-year-oldgentleman and a 58-year-old gentleman both diagnosedwith a rare malignant tumour resident on an islandinhabited by 420,000 people. Both tumours showed tobe very aggressive in nature and were both inoperableat presentation.Park et al.7 concluded that not a single patient withadvanced malignant solitary fibrous tumour showedcomplete or partial response to conventionalchemotherapy although a large proportion remained
with stable disease7. Tyrosine kinase inhibitors such assunitinib have shown some promise in the treatment ofSFTs.10 Also, a temozolomide-bevacizumab combinationappear to have greater efficacy in treating SFTs thanconventional chemotherapy such as doxorubicin-ifosfamide combinations.11Imatinib mesylate works as a tyrosine kinase inhibitortargeting the PDGFR, the BCR-ABL, and c-KIT receptors.4Imatinib is thought to be a potential treatment formalignant SFTs in tumour cells found to be positive forPDGFR-α and PDGFR-β, in the absence of c-KIT andPDGRFR mutations6, 9 Tyrosine kinase inhibitors mightgive beneficial effects in slowing disease progression in anumber of patients, however, our patients only survivedabout 4 months after imatinib was started.
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